EMAIL THIS PAGE TO A FRIEND

The Journal of antimicrobial chemotherapy

Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.


PMID 24951535

Abstract

T-705, also known as favipiravir, is a small-molecule inhibitor that is currently in clinical development for the treatment of influenza virus infections. This molecule also inhibits the replication of a broad spectrum of other RNA viruses. The objective of this study was to investigate the antiviral effect of favipiravir on chikungunya virus (CHIKV) replication and to contribute to unravelling the molecular mechanism of action against this virus. The anti-CHIKV effect of favipiravir was examined in cell culture and in a mouse model of lethal infection. A five-step protocol was used to select for CHIKV variants with reduced susceptibility to favipiravir. The resistant phenotype was confirmed in cell culture and the whole genome was sequenced. The identified mutations were reverse-engineered into an infectious clone to confirm their impact on the antiviral efficacy of favipiravir. Favipiravir inhibits the replication of laboratory strains and clinical isolates of CHIKV, as well as of a panel of other alphaviruses. Several favipiravir-resistant CHIKV variants were independently selected and all of them in particular acquired the unique K291R mutation in the RNA-dependent RNA polymerase (RdRp). Reverse-engineering of this K291R mutation into an infectious clone of CHIKV confirmed the link between the mutant genotype and the resistant phenotype. Interestingly, this particular lysine is also highly conserved in the RdRp of positive-stranded RNA viruses in general. This study provides an important insight into the precise molecular mechanism by which favipiravir exerts its antiviral activity against (alpha)viruses, which may be of help in designing other potent broad-spectrum antivirals.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A9415
Actinomycin D, from Streptomyces sp., suitable for cell culture, ≥95%
C62H86N12O16
A4262
Actinomycin D, from Streptomyces sp., ≥95% (HPLC)
C62H86N12O16
02685
Lithium atomic spectroscopy standard concentrate 1.00 g Li, for 1 l standard solution, 1.00 g/L, analytical standard
ClLi
746460
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
ClLi
793620
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
ClLi
L4408
Lithium chloride, BioXtra, ≥99.0% (titration)
ClLi
62476
Lithium chloride, BioUltra, for molecular biology, anhydrous, ≥99.0% (AT)
ClLi
L9650
Lithium chloride, for molecular biology, ≥99%
ClLi
429457
Lithium chloride, anhydrous, beads, −10 mesh, 99.998% trace metals basis
ClLi
449881
Lithium chloride, anhydrous, beads, −10 mesh, ≥99.9% trace metals basis
ClLi
203637
Lithium chloride, powder, ≥99.99% trace metals basis
ClLi
HT-LICLSLUG
Lithium chloride, anhydrous, chunks, 99.99% trace metals basis
ClLi
751898
Lithium chloride, anhydrous, chunks, 99.99% trace metals basis
ClLi
L7026
Lithium chloride solution, 8 M, for molecular biology, ≥99%
ClLi
694576
Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone
ClLi
62483
Lithium chloride solution, 1 M in glacial acetic acid
ClLi
62481
Lithium chloride solution, 1 M in ethanol
ClLi
667544
Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran
ClLi
LCL30
Lithium chloride solution, 2 M in ethanol
ClLi
601489
Lithium-7Li chloride, 99 atom % 7Li, 99% (CP)
Cl7Li
P9625
Phenazine methosulfate, ≥90% (UV)
C14H14N2O4S
1613655
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard
CHNaO3
71631
Sodium bicarbonate, tested according to Ph.Eur.
CHNaO3